Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $110.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target lifted by Wells Fargo & Company from $87.00 to $110.00 in a research note published on Wednesday,Benzinga reports. The firm currently has an overweight rating on the stock.

KNSA has been the subject of a number of other research reports. Citigroup raised their target price on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Canaccord Genuity Group upped their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Weiss Ratings raised shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. The Goldman Sachs Group increased their price target on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Finally, Wedbush raised their price objective on shares of Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $100.57.

Kiniksa Pharmaceuticals International Stock Down 5.5%

Shares of Kiniksa Pharmaceuticals International stock opened at $92.24 on Wednesday. The firm has a market cap of $7.20 billion, a price-to-earnings ratio of 70.95 and a beta of 0.04. Kiniksa Pharmaceuticals International has a 52-week low of $36.56 and a 52-week high of $98.48. The company’s 50-day simple moving average is $79.15 and its 200-day simple moving average is $60.03.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The firm had revenue of $285.97 million during the quarter, compared to the consensus estimate of $260.66 million. Equities research analysts anticipate that Kiniksa Pharmaceuticals International will post 1.26 EPS for the current year.

Insider Activity at Kiniksa Pharmaceuticals International

In other news, CAO Michael Megna sold 4,600 shares of the firm’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total value of $369,380.00. Following the transaction, the chief accounting officer owned 29,062 shares of the company’s stock, valued at approximately $2,333,678.60. This trade represents a 13.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 51.98% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Several large investors have recently added to or reduced their stakes in the stock. Rubric Capital Management LP increased its stake in shares of Kiniksa Pharmaceuticals International by 12.7% in the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock valued at $180,562,000 after purchasing an additional 421,347 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Kiniksa Pharmaceuticals International by 18.8% during the first quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock valued at $39,086,000 after buying an additional 128,417 shares during the last quarter. Spruce Street Capital LP boosted its position in shares of Kiniksa Pharmaceuticals International by 75.0% during the first quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock worth $36,645,000 after buying an additional 326,081 shares during the period. Bank of America Corp DE boosted its position in shares of Kiniksa Pharmaceuticals International by 220.9% during the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock worth $35,436,000 after buying an additional 506,576 shares during the period. Finally, Rice Hall James & Associates LLC boosted its position in shares of Kiniksa Pharmaceuticals International by 2.0% during the first quarter. Rice Hall James & Associates LLC now owns 608,416 shares of the company’s stock worth $29,295,000 after buying an additional 11,985 shares during the period. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.